We serve Chemical Name:(phthalimido-4-aminomethyl)piperidine CAS:153747-01-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(phthalimido-4-aminomethyl)piperidine
CAS.NO:153747-01-4
Synonyms:4-PHOSPHONOPHENYLGLYCINE;4-phthalimidomethylpiperidine
Molecular Formula:C14H17N3O2
Molecular Weight:259.30400
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:66.64000
Exact Mass:259.13200
LogP:1.44440
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-PHOSPHONOPHENYLGLYCINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-phthalimidomethylpiperidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-PHOSPHONOPHENYLGLYCINE Use and application,4-phthalimidomethylpiperidine technical grade,usp/ep/jp grade.
Related News: As currently constituted, Vanamali employs roughly 140 works in Hyderabad, Telangana, that specialize in API starting materials and contract research, according to its website. Wavelength said the Indian firm currently sports enough capacity for research- to commercial-scale production of its drug intermediates. ethyl 2-(3,4-dicyanophenoxy)acetate manufacturers Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug. 3-(o-acetoxyphenyl)-1-phenylprop-2-yn-ol suppliers AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023. 3-acetyl-6-chloro-3H-benzooxazol-2-one vendor & factory Throughout the pandemic, our site remained fully operational while keeping our employees safe and having a positive impact on human health. Our expanded facility will provide us with the increased capacity needed to continue the essential services we provide to our clients”,AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023.
